STING1 and neoplasm: STING pathway activation has been reported to upregulate PD‐L1 expression on tumor cells, potentially diminishing therapeutic efficacy by enhancing immune checkpoint signaling.[3, 23, 24] To counter this, PD‐L1 antibodies are commonly used to block immune checkpoints and prevent immune escape.